A methylated GHRP-6 analog with higher potency. Distinctive for secondary binding at CD36, a scavenger receptor expressed in cardiac tissue, which has driven separate investigation into cardiovascular effects independent of GH release. Marked tachyphylaxis — GH response attenuates with continued exposure.
Studied in early human work for GH release and in preclinical cardiac models. No approved indication; efficacy unestablished.
Not FDA-approved. Prohibited in sport (WADA S2).
Desensitisation with repeated exposure. Cortisol/prolactin effects. Long-term safety uncharacterised.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.